The purpose of this study is to evaluate the effectiveness and safety of a computed tomography (CT)-guided, multidisciplinary, minimally invasive approach to the treatment of patients with large, refractory malignant fibrous histiocytoma. This approach includes microwave ablation and absolute alcohol therapy combined with 125 I seed implantation. Seven patients (5 males and 2 females, 26-78 years old, mean 49.7 years old) with large, refractory malignant fibrous histiocytoma participated in this study. The tumors had an average maximum diameter of 14.1 cm (10.0-19.0 cm). Follow-up was conducted for an average of 35.7 months to determine the local control rate, overall survival rate, and clinical complications. Followup times ranged from 2 to 45 months. Pain was significantly relieved in patients treated with multidisciplinary, minimally invasive approach. Complete response was achieved in 5 patients (71.4%), partial response in the other 2 patients (28.6%). The response rate of this treatment was 100%. The median survival time was 35.7 months. All patients were alive in 2 years after the treatment. Five patients were still alive after 3 years. The 3 year survival rate was 71.4%. The long-term complications included hyperpigmentation at the operative sites (n 5 5) and insensible feeling at the ablation sites (n 5 3).This CT-guided multidisciplinary, minimally invasive approach is an effective, safe, and feasible means of treating large, refractory malignant fibrous histiocytoma with minimal damage and few complications, but large-scale randomized clinical trials are necessary to confirm this assessment.
Introduction
Malignant fibrous histiocytoma (MFH) is a type of pleomorphic sarcoma and its principal components are the appearance of fibroblasts and histiocytoid cells. Soft tissue MFHs occur most often in the lower limbs, followed by the upper limbs and retroperitoneum. Most originate in the deep layer of the deep fascia (1) (2) (3) .
The primary treatment for MFH is surgical resection aided by radiation and chemotherapy (4) (5) (6) (7) (8) . There is no standard treatment for tumors that cannot be removed with surgery or cancer cells that have metastasized. In these situations, both treatment and prognosis are poor. MFH is highly malignant (9) . The treatment for late MFH, which can cause both large tumors and metastasis, is difficult. In this study, we adopted microwave ablation and ethanol injection combined with 125 I seed implantation for the treatment of the late-stage MFH tumors that have extended to adjacently important vessels, nerves, and organs, and cannot be removed with surgery (10) (11) (12) . The ethanol used in this project was pure alcohol at 100% concentration. When it was injected into the tumor lesions or into normal tissue, it immediately caused the cell proteins to coagulate, causing necrosis and microvascular blocks. This method is simple and cheaper than other therapeutic method. Considering to the size of the tumors, coordinated microwave ablation and ethanol injection combination therapy has fewer side effects than most single treatments, and it can also reduce costs and improve patients ' treatment tolerance. 125 I seed implantation used to treat cancers adjacent to important vessels, nerves, and organs, to avoid damaging them. This paper presents an evaluation of the efficacy and security of microwave ablation and ethanol injection combined with 125 I seed implantation for the treatment of large, refractory MFHs.
Materials and Methods

Patient Selection
From June 2007 to May 2011, 7 patients were enrolled in this prospective clinical trial, which was approved by the ethical committee of the Sun Yat-Sen University Cancer Center. All patients provided written informed consent before entering the study. Patients were informed of the potential risks and benefits of the treatment.
Eligibility and Exclusion Criteria
Study eligibility criteria were as follows: (a) Diagnosis of MFH confirmed by needle biopsy; (b) lesion diameter of over 8 cm; (c) tumor infringement upon neighboring tissue organizations or organs without distant metastasis; (d) Patients had to have inoperable tumor and be willing to participate in the trial; (e) those non-responsive to multiple courses of chemotherapy but rejecting surgery due to the larger risk; (f) Positron emission tomography-Computed tomography (PET/CT) results indicating tumors arranged in a localized way conducive to minimally invasive treatment; (g) Karnofsky performance scale score of 70% or greater; (h) no severe unstable hematogenic parameters or active infection. Study exclusion criteria were as follows: (a) fever or infectious disease, (b) advanced cardiac or pulmonary disease, (c) evidence of metastasis.
Patients
Seven patients (five men and two women) with a mean age of 49.7 years (range, 26-78 years) were treated using a multidisciplinary strategy. Tumor diameter varied from 10.0 to 19.0 cm (mean, 14.1 cm). All patients were diagnosed by biopsy. The characteristics of individual patients and tumors are summarized in Table I .
Therapeutic Principles
The principle of the multidisciplinary therapy for the large, unresectable MFH is as follows: Microwave ablation is used with tumors that lack blood supplies, as shown by images. Ethanol injection is used for tumors with rich blood supplies. 125 I seed implantation is used to treat tumors adjacent to important vessels, nerves, and organs.
Microwave Ablation and Absolute Alcohol Therapy
Tumor activity was detected by abnormal radioactivity concentrations observed on PET images. CT scans were also obtained. The location and extent of the lesions present and the needle route to be used were determined on PET/CT scans. The microwave ablation treatments were performed with patients under general anesthesia. A 14-guage cooledshaft antenna was placed into the tumor focus. The electrode needle of the microwave device was connected to the output machine of the microwave instrument via a flexible coaxial cable, and a cooling water tube was connected to that. The constant flow pump was switched on to ascertain the functionality of the cold water cycling system. The microwave power was set at 60-80 W. The first ablation began at the location farthest away from the skin puncture site. After the ablation was completed, the needle was withdrawn to the second predetermined location.
The first step of absolute alcohol therapy was the insertion of a 22-gauge needle into the tumors. Absolute alcohol was slowly injected into the portion of the tumor farthest away from the skin puncture site and then into the rest of the tumor. Particular attention was paid to injection of the parts of the tumor where the microwave ablation was likely to be incomplete, such as near large vessels, gall bladder, and subcapsular region. The amount of mixture (iodized oil and ethanol at a ratio of 1:9) injected into the tumors was determined according to the size of the tumors and was always kept below the estimated volume of the tumor: V 5 4/3π (r 1 0.5)3 (r: radius of tumor, in cm). Injection of ethanol was stopped if resistance to the injection was felt.
I Brachytherapy Planning and Seed Implantation
The dose prescribed as the minimal peripheral dose (MPD) encompassed the planning target volume (PTV). The median MPD was 130 Gy (range, 90-160). The distribution and MPD of 125 I seeds were calculated using a computerized treatment planning system (TPS) (RT-RSI, Beijing Atom and High Technique Industries Inc., Beijing, China).
For each patient, a 5-mm incision was made in the skin and a brachytherapy applicator was inserted into each tumor under the guidance of PET/CT. Precautions were taken to avoid puncturing any large blood vessels or important organs. For tumors with a thickness 1.0 cm, interstitial planar (surface) implants were used. 125 I seeds with an activity of 0.8 mCi were implanted into each tumor. The anti-tumor activity of these seeds extended over a radius of 1.7 cm. Upon completion of the procedure, catheters were retracted and incisions were bound and compressed. Within a month of the procedure, a PET/CT and CT scans were performed to verify that the position and intensities of the implanted 125 I seeds by TPS. If the level or extent of radioactivity was found to be insufficient, additional 125 I seeds were implanted. All patients were successfully implanted.
Effect Evaluation
Pain: Pain degree was classified using verbal rating scales (VRS). Patients were asked to respond 0 for no pain, 1 for mild pain, 2 for moderate, and 3 for severe (13) . 
Tumors
Follow-up
Vital signs were monitored for 24 hours after the operation.
All changes from the symptoms seen at presentation were recorded. A clinical examination was performed after one month post-procedure and PET-CT was evaluated. Every 2 to 3 months post-procedure, follow-up imaging examinations were performed to evaluate the therapeutic effectiveness of the therapy. All patients underwent pre-and post-treatment PET-CT examinations. Treatment response was evaluated according to the RECIST (14) .
Results
Treatment Data
The 125 I seed implantation procedure required 60-180 minutes and was guided by PET/CT scan imaging according to the established TPS. The median number of seeds implanted per patient was 176 (range, 135-220). The patients underwent 2-8 implantation sessions (mean, 5.0 sessions). Microwave power was set at 60-80 W. The coagulation total time for tumor focus was 180-350 minutes. The mean total amount of absolute alcohol used was 77.1 ml (range, 30-110 ml) (Table II) .
Follow-up Imaging
PET/CT imaging performed prior to the multidisciplinary approach treatment revealed abnormal radioactivity concentrations present in all of the tumors imaged. When the same imaging was performed 2 months after the multidisciplinary approach treatment, the abnormal radioactivity concentration previously observed had disappeared, and was replaced by a cold lesion which exhibited the size and shape of the inactivated tumor (Figures 1 and 2) .
Effect Evaluation
Pain Relief: The numbers of patients with moderate and severe pain pre-treatment were 4 and 3, respectively. After treatment, . (A, B) The imaging of PET/CT before multidisciplinary minimally invasive treatment showed abnormal radioactivity concentration in the right cavitas thoracis, and the second and third vertebral body had been demaged by tumor (July 20, 2006) . (C, D, E) The imaging of PET/CT after multidisciplinary minimally invasive treatment revealed the mostly absence of abnormal radioactivity concentration and came into a mostly cold lesion in the right cavitas thoracis, which is indicative of mostly coagulation necrosis in the right cavitas thoracis malignant fibrous histiocytoma (July 10, 2008). PET/CT 5 Positron emission tomography/Computed tomography. 5 patients saw their pain disappear without analgesics. Two patients who continued to experience mild pain required less medication than before treatment.
Local Control and Survival:
Two months after the multidisciplinary approach treatment, PET/CT and CT examination confirmed that treatment had been effective in all patients: 5 CR (71.4%), 2 PR (28.6%). The response rate was 100%. For the 7 advanced MFH patients, 2 patients died within a few years (survival time, 29 and 38 months) and five were still alive at the end of follow-up, which lasted 25, 36, 37, 40, and 45 months, respectively. The median survival time was 35.7 months. All patients were alive after 2 years of multidisciplinary approach treatment. Five patients remained alive after 3 years. One patient died as a result of cachexia and infection during the 3rd year, the other patient died of lung dysfunction caused by pulmonary metastases after 2 years. The 3-year survival rate was 71.4% (Table II) . 
Complications
After treatment, low-grade fever arose in five patients, which resolved 3-4 days later. During patient follow-up, long-term complications included hyperpigmentation at the operative sites (n 5 5) and lack of feeling at the ablation sites (n 5 3). None of the patients reported bleeding, infection, bone marrow suppression, or ectopic embolization. No severe complication was observed and no unexpected side effects were noted after multidisciplinary treatment.
Discussion
The principle of the multidisciplinary therapy for large, unresectable MFHs is as follows: microwave ablation for tumors lacking blood supply, as indicated by images, ethanol injection for tumors with rich blood supplies, 125 I seed implantation for tumors adjacent to important vessels, nerves, and organs.
MFH, which was first reported by O'Brien and Stout (17), accounts for about 5% of soft tissue sarcomas. Bedrossian first reported a lung primary MFH fist in 1979 (18, 19) . Most scholars believe that its histologic origin is undifferentiated mesenchymal tissue. Within the tumors, a number of cell elements can appear. These can differentiate into organization cells and then differentiate into phagocytic cells and fiber mother cells. They also can produce a few reticular and collagen fibers. MFHs can be divided into four types: pleomorphic, mucous, giant, and xanthoma, from high incidence to low (20, 21) . MFH is a kind of common malignant tumor of the soft tissue. It is easily seen in the elderly. It mainly occurs in the limbs, in men more than in women. Treatment can often fail, showing up as local recurrence and hematogenous and pulmonary metastasis.
The best means of addressing MFH is early discovery and timely treatment. Before any operation, a correct judgment of the tumor growth area of whether the tumor infringes upon any important organs or tissues, and of whether the tumor is likely to recur must be performed needed to establish the range and depth of operation and a reasonable operation program. This not only maximizes the resection and reduces the risk of recurrence and metastasis, but also protects patient limb function. At present, the primary MFH treatment is surgical operation. Wide surgical resections operation are used, removing healthy as well as diseased tissue in order to reduce the chance of local recurrence, (22) (23) (24) However, because of the tumors' capacity to infiltrate other tissues, they often invade the neighboring tissues and organs. In order to reduce recurrence, supplementary radiation must be administered to suspicious tumor beds after the operation. The roentgenization of tumor remnants and surrounding clinical lesions can control tumor recurrence effectively. Preoperative radiation therapy should not be advocated because MFH is not sensitive to radiotherapy. Preoperative radiation therapy is more likely to delay the operation than to provide any benefits. Local resection can be used for any tumors that occur after the operation and radiotherapy. Wild radiotherapy can also be set as needed. Upon relapse, prognosis is poor.
The currently accepted factors that influence the prognosis of patients with MFH are tumor size, pathological classification, and pathological type. Some studies have made it clear that MFH tumors of over 10 cm in diameter indicate poor prognosis (25) .
In our study, seven patients with large, unresectable MFH were treated with a multidisciplinary minimally invasive approach. This multidisciplinary approach included microwave ablation, absolute alcohol therapy and 125 I seed implantation. Because these tumors had invaded adjacent surrounding tissues, simple physical ablation was not sufficient for complete tumor necrosis. We chose microwave ablation and ethanol injection combined with 125 I seed implantation for the treatment of large, unresectable MFHs. Microwave ablation was adopted for tumors lacking of blood supply, as shown by images, ethanol injection for tumors with rich blood supplies, and 125 I seed implantation for tumors adjacent to important vessels, nerves, and organs. In this study, some tumor lesions had invaded the vertebral body, as the disease develops, this can lead to the paralysis or even death. We implanted 125 I seeds beside the vertebral body to kill the tumor cells and to act as a wall, preventing the tumor from invading the vertebral body and slowing the development of the disease.
Pain management for patients with large, unresectable MFHs is an ongoing challenge. All 7 of our patients experienced pain. After receiving multidisciplinary minimally invasive treatment, pain was significantly alleviated in all patients. One possible mechanism for pain relief may be thermal periostial denervation. Another possible mechanism may be related to the thermal ablation of the tumor tissue mass itself; through reduction in mass, the pressure on adjacent healthy tissues might be relieved. A combination of these mechanisms is also possible.
